Literature DB >> 25668362

Clinical observation of liver cancer patients treated with axitinib and cabozantinib after failed sorafenib treatment: a case report and literature review.

Bin Zhang1, Xia Zhang, Tao Zhou, Jiwei Liu.   

Abstract

Hepatocellular carcinoma (HCC) is a major pathological type of primary liver cancer. Sorafenib has demonstrated definite efficacy in targeted therapy for HCC. However, when treatment with sorafenib fails, suitable drugs must be found for further treatment. This article reports a case of an HCC patient who was treated with angiogenesis inhibitor axitinib and c-Met inhibitor cabozantinib following treatment with sorafenib. The report focuses on clinical treatment and toxicity. Rational application of targeted therapy is also explored.

Entities:  

Keywords:  Alpha-fetoprotein; Axitinib; Cabozantinib; Hepatocellular carcinoma; Primary liver cancer; Sorafenib; c-Met

Mesh：

Substances：

Year:  2015        PMID： 25668362      PMCID： PMC4622678          DOI： 10.4161/15384047.2014.962318

Source DB:  PubMed          Journal:  Cancer Biol Ther        ISSN： 1538-4047            Impact factor:   4.742


  15 in total

1.  Phase 2 study of bevacizumab plus erlotinib in patients with advanced hepatocellular cancer.

Authors:  Philip A Philip; Michelle R Mahoney; Kyle D Holen; Donald W Northfelt; Henry C Pitot; Joel Picus; Patrick J Flynn; Charles Erlichman
Journal:  Cancer       Date:  2011-09-27       Impact factor: 6.860

2.  Regorafenib as second-line therapy for intermediate or advanced hepatocellular carcinoma: multicentre, open-label, phase II safety study.

Authors:  Jordi Bruix; Won-Young Tak; Antonio Gasbarrini; Armando Santoro; Massimo Colombo; Ho-Yeong Lim; Vincenzo Mazzaferro; Reiner Wiest; María Reig; Andrea Wagner; Luigi Bolondi
Journal:  Eur J Cancer       Date:  2013-06-25       Impact factor: 9.162

3.  Continuous Sunitinib treatment in patients with advanced hepatocellular carcinoma: a Swiss Group for Clinical Cancer Research (SAKK) and Swiss Association for the Study of the Liver (SASL) multicenter phase II trial (SAKK 77/06).

Authors:  Dieter Koeberle; Michael Montemurro; Panagiotis Samaras; Pietro Majno; Mathew Simcock; Andreas Limacher; Stefanie Lerch; Katalin Kovàcs; Roman Inauen; Vivianne Hess; Piercarlo Saletti; Markus Borner; Arnaud Roth; György Bodoky
Journal:  Oncologist       Date:  2010-03-04

4.  Brivanib in patients with advanced hepatocellular carcinoma who were intolerant to sorafenib or for whom sorafenib failed: results from the randomized phase III BRISK-PS study.

Authors:  Josep M Llovet; Thomas Decaens; Jean-Luc Raoul; Eveline Boucher; Masatoshi Kudo; Charissa Chang; Yoon-Koo Kang; Eric Assenat; Ho-Yeong Lim; Valerie Boige; Philippe Mathurin; Laetitia Fartoux; Deng-Yn Lin; Jordi Bruix; Ronnie T Poon; Morris Sherman; Jean-Frédéric Blanc; Richard S Finn; Won-Young Tak; Yee Chao; Rana Ezzeddine; David Liu; Ian Walters; Joong-Won Park
Journal:  J Clin Oncol       Date:  2013-08-26       Impact factor: 44.544

5.  Brivanib versus sorafenib as first-line therapy in patients with unresectable, advanced hepatocellular carcinoma: results from the randomized phase III BRISK-FL study.

Authors:  Philip J Johnson; Shukui Qin; Joong-Won Park; Ronnie T P Poon; Jean-Luc Raoul; Philip A Philip; Chih-Hung Hsu; Tsung-Hui Hu; Jeong Heo; Jianming Xu; Ligong Lu; Yee Chao; Eveline Boucher; Kwang-Hyub Han; Seung-Woon Paik; Jorge Robles-Aviña; Masatoshi Kudo; Lunan Yan; Abhasnee Sobhonslidsuk; Dmitry Komov; Thomas Decaens; Won-Young Tak; Long-Bin Jeng; David Liu; Rana Ezzeddine; Ian Walters; Ann-Lii Cheng
Journal:  J Clin Oncol       Date:  2013-08-26       Impact factor: 44.544

6.  Sunitinib versus sorafenib in advanced hepatocellular cancer: results of a randomized phase III trial.

Authors:  Ann-Lii Cheng; Yoon-Koo Kang; Deng-Yn Lin; Joong-Won Park; Masatoshi Kudo; Shukui Qin; Hyun-Cheol Chung; Xiangqun Song; Jianming Xu; Guido Poggi; Masao Omata; Susan Pitman Lowenthal; Silvana Lanzalone; Liqiang Yang; Maria Jose Lechuga; Eric Raymond
Journal:  J Clin Oncol       Date:  2013-09-30       Impact factor: 44.544

7.  Cabozantinib suppresses tumor growth and metastasis in hepatocellular carcinoma by a dual blockade of VEGFR2 and MET.

Authors:  Qingfeng Xiang; Weiqiang Chen; Meng Ren; Jingnan Wang; Hongwu Zhang; David Y B Deng; Lei Zhang; Changzhen Shang; Yajin Chen
Journal:  Clin Cancer Res       Date:  2014-04-03       Impact factor: 12.531

8.  Tivantinib for second-line treatment of advanced hepatocellular carcinoma: a randomised, placebo-controlled phase 2 study.

Authors:  Armando Santoro; Lorenza Rimassa; Ivan Borbath; Bruno Daniele; Stefania Salvagni; Jean Luc Van Laethem; Hans Van Vlierberghe; Jörg Trojan; Frank T Kolligs; Alan Weiss; Steven Miles; Antonio Gasbarrini; Monica Lencioni; Luca Cicalese; Morris Sherman; Cesare Gridelli; Peter Buggisch; Guido Gerken; Roland M Schmid; Corrado Boni; Nicola Personeni; Ziad Hassoun; Giovanni Abbadessa; Brian Schwartz; Reinhard Von Roemeling; Maria E Lamar; Yinpu Chen; Camillo Porta
Journal:  Lancet Oncol       Date:  2012-11-20       Impact factor: 41.316

9.  Klotho endows hepatoma cells with resistance to anoikis via VEGFR2/PAK1 activation in hepatocellular carcinoma.

Authors:  Lin Chen; Haiou Liu; Jing Liu; Yu Zhu; Le Xu; Hongyong He; Heng Zhang; Shanshan Wang; Qian Wu; Weisi Liu; Yidong Liu; Deng Pan; Shifang Ren; Jiejie Xu; Jianxin Gu
Journal:  PLoS One       Date:  2013-03-13       Impact factor: 3.240

Review 10.  Drug therapy for advanced-stage liver cancer.

Authors:  Markus Peck-Radosavljevic
Journal:  Liver Cancer       Date:  2014-05       Impact factor: 11.740
View more
  2 in total

1.  The Clinical Impact of Transcatheter Arterial Chemoembolization (TACE)-Induced c-Met Upregulation on TACE Refractoriness in Hepatocellular Carcinoma.

Authors:  Jun Kajihara; Yoshito Tomimaru; Hidetoshi Eguchi; Daisaku Yamada; Hiroshi Wada; Akira Tomokuni; Tadafumi Asaoka; Koichi Kawamoto; Shigeru Marubashi; Hiroaki Nagano; Koji Umeshita; Yuichiro Doki; Masaki Mori
Journal:  Dig Dis Sci       Date:  2016-01-02       Impact factor: 3.199

2.  TRIM8 restores p53 tumour suppressor function by blunting N-MYC activity in chemo-resistant tumours.

Authors:  Francesca Mastropasqua; Flaviana Marzano; Alessio Valletti; Italia Aiello; Giuseppe Di Tullio; Annalisa Morgano; Sabino Liuni; Elena Ranieri; Luisa Guerrini; Giuseppe Gasparre; Elisabetta Sbisà; Graziano Pesole; Antonio Moschetta; Mariano Francesco Caratozzolo; Apollonia Tullo
Journal:  Mol Cancer       Date:  2017-03-21       Impact factor: 27.401
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.